VKTX Viking Therapeutics Inc.

1.39
+0.15  (12%)
Previous Close 1.24
Open 1.24
Price To book 5.79
Market Cap 38499225
Shares 27,697,284
Volume 532,832
Short Ratio 1.87
Av. Daily Volume 199,148

SEC filingsSee all SEC filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 171018720
  2. 8-K - Current report 171018050
  3. 8-K - Current report 17950863
  4. CT ORDER - Confidential treatment order 17932344
  5. D - Notice of Exempt Offering of Securities 17925494

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data due 1H 2018.
VK2809
Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease
Phase 2 completion of enrollment announced July 12, 2017 with data due 4Q 2017.
VK5211
Acute Hip Fracture

Latest News

  1. Should You Buy Viking Therapeutics Inc (VKTX) Now?
  2. VKTX: Encouraging In Vivo Data For VK2809 From Mouse Model of GSD 1a and Gene Expression Analysis in Mouse Model of NASH
  3. Viking Therapeutics Announces Results of Gene Expression Analysis from In Vivo Study of VK2809 in Non-Alcoholic Steatohepatitis (NASH)
  4. Viking Therapeutics Announces Presentation of Data from In Vivo Proof-of-Concept Study of VK2809 in Glycogen Storage Disease Ia (GSD Ia) at the 13th International Congress of Inborn Errors of Metabolism (ICIEM)
  5. Viking Therapeutics to Present at Rodman & Renshaw's 19th Annual Global Investment Conference
  6. VKTX: Data From Phase 2 Trial of VK5211 Expected in 4Q17
  7. Viking Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update
  8. Viking Therapeutics to Report Financial Results for Second Quarter 2017 After Market Close on August 9, 2017
  9. Corporate News Blog - Viking Therapeutics Completes Enrollment in Phase-2 study of VK5211 in Patients Recovering from Hip Fracture
  10. Viking Therapeutics Completes Enrollment in Phase 2 Study of VK5211 in Patients Recovering from Hip Fracture
  11. Viking Therapeutics Appoints Charles A. Rowland Jr. to Board of Directors
  12. VKTX Raises $4.3 Million in Gross Proceeds From Registered Direct Offering…
  13. Viking Therapeutics Announces $4.3 Million Registered Direct Offering
  14. VKTX: Potential of VK2809 in NASH Treatment Shown in Diet-Induced Mouse Model
  15. Viking Therapeutics Announces Promising Top Line Results from In Vivo Study of VK2809 in Non-Alcoholic Steatohepatitis (NASH)
  16. Viking Therapeutics to Present at Upcoming Investor Conferences
  17. VKTX: Multiple Data Readouts Ahead in 2017
  18. Viking Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update
  19. Viking Therapeutics to Report Financial Results for First Quarter 2017 After Market Close on May 10, 2017
  20. Viking Therapeutics to Present at H.C. Wainwright & Co.'s 1st Annual NASH Investor Conference

SEC Filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 171018720
  2. 8-K - Current report 171018050
  3. 8-K - Current report 17950863
  4. CT ORDER - Confidential treatment order 17932344
  5. D - Notice of Exempt Offering of Securities 17925494
  6. 8-K - Current report 17918847
  7. 424B5 - Prospectus [Rule 424(b)(5)] 17914192
  8. 8-K - Current report 17910409
  9. 8-K - Current report 17866852
  10. 10-Q - Quarterly report [Sections 13 or 15(d)] 17831546